CATX

#3166
Perspective Therapeutics, Inc. Common Stock
3.1 3 USD
+0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
3.11
3.14
Jahresspanne
1.96
6.16
Tagesänderung
+1.29%
Monatliche Änderung
+7.56%
6 month change
-39.69%
Jahresänderung
-7.40%
Vorheriger Schlusskurs
3.0 9
Open
3.1 1
Tief
3.1 1
Hoch
3.1 4
Volumen
183
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Perspective Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Perspective Therapeutics, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Perspective Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Perspective Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Perspective Therapeutics, Inc. current report, Q2 FY2026
8-K

Perspective Therapeutics, Inc. current report, Q2 FY2025

Full document

Business Context and Reporting Period

This Form 8-K reports on the results of the 2025 Annual Meeting of Stockholders held by Perspective Therapeutics, Inc. on May 28, 2025. The company is incorporated in Delaware and its common stock trades on NYSE American under the symbol CATX.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.

Material Changes and Voting Results

Of the 74,050,841 shares outstanding, 60,850,291 shares (82.17%) were represented at the meeting, constituting a quorum. The following matters were voted upon:

  • Proposal 1 (Election of Directors): Stockholders elected Lori A. Woods, Heidi Henson, Frank Morich, M.D., Ph.D., Johan (Thijs) Spoor, and Robert Froman Williamson, III to the Board. All nominees received majority support, though Heidi Henson and Robert Froman Williamson, III received significant "Withheld" votes (approximately 17.6% and 17.5% respectively).
  • Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The proposal passed with 59,126,140 votes "For" versus 1,584,010 "Against".
  • Proposal 3 (Say on Pay): Stockholders approved the compensation of named executive officers on a non-binding advisory basis. The proposal passed with 38,730,185 votes "For" versus 13,686,122 "Against".

Guidance, Outlook, and Risks

The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the standard disclosure of voting results.

Investor Verification Checklist

  • Verify the specific reasons for the high "Withheld" vote percentages for directors Heidi Henson and Robert Froman Williamson, III.
  • Review the proxy statement referenced in the filing for details on the executive compensation package approved in Proposal 3.
  • Confirm the tenure of the newly elected board members, which extends until the 2026 Annual Meeting.

Nachrichten